TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04740138

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavioral Therapy Skills + Parent Training
Description: The DBT/Parent training group intervention is a novel integration of three evidence-based treatments (i.e. DBT Skills, Parent Management Training (PMT), and Emotion Coaching (EC)). The DBT Skills portion of each session follows the DBT Skills Training Manual Second Edition and DBT Skills Training Handouts and Worksheets Second Edition. DBT Skills portions cover the four modules of traditional DBT Skills: mindfulness, distress tolerance, emotion regulation and interpersonal effectiveness.~PMT portions of the intervention cover: praise, positive interactions and parental attention, reward systems, effective commands, use of consequences, and problem solving. EC portions of the intervention cover: psychoeducation on children's emotional development, teaching children to identify and label emotions, validation of children's emotions, handling children's negative emotions, fostering children's positive emotions and parental modeling of emotion regulation and expression.
Study: NCT03126344

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: King Vision video laryngoscope
Description: nasal intubation using King Vision video laryngoscope Device after general anesthesia induction

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: McGrath MAC video laryngoscope
Description: nasal intubation using McGrath MAC video laryngoscope Device after general anesthesia induction

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh laryngoscope
Description: nasal intubation using Macintosh laryngoscope Device after general anesthesia induction
Study: NCT00490529

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CpG-MCL vaccine
Description: CpG-MCL vaccine is a vaccine prepared by co-culturing cells from the participant's mantle cell lymphoma suspension with 3 mcg/mL PF-3512676, then irradiated to 200 Gy. 1 x 10e8 CpG-MCL cells will be given as a subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-3512676
Description: PF-03152676 is a synthetic immunostimulatory, single-stranded oligodeoxynucleotide (oligo-DNA) moledule containing unmethylated cytosine and guanine (CpG) motifs. PF-03512676 acts as an agonist of human Toll-like receptor 9, leading to activation of antigen-presenting cells and a cascade of antitumor immune reactions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vaccine-primed T-cells
Description: Vaccine primed T-cells are the post-vaccination leukapheresis harvest of peripheral blood mononuclear cells. Each collection is approx 1 x 10e10 CD3+ T-cells.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplant (HSCT)
Description: Regular medical procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m² by infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard induction chemotherapy
Description: Patient-specific, regular medical care treatment as determined by treating oncologist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Regular medical care treatment to mobilize peripheral blood progenitor cell (PBPC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Regular medical care treatment to mobilize peripheral blood progenitor cell (PBPC)
Study: NCT02600819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Description: 150/150/200/10 mg FDC tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: 50/200/25 mg FDC tablets administered orally once daily
Study: NCT01328405

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Description: Comparison of airway seal pressure, airway morbidity bronchoscopic view obtained between two different laryngeal mask airways.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Description: Comparison of airway seal pressure, airway morbidity bronchoscopic view obtained between two different laryngeal mask airways.
Study: NCT00296296

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporin
Description: Dose adjustment to pre-established targets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Dose adjustment to pre-established targets

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 'Diabetes Education / Management'
Description: therapeutic adjustment to target ADA criteria

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 'Diabetes Education / Management'
Description: therapeutic adjustment to target ADA criteria
Study: NCT04280237

Intervention type: OTHER
Intervention: Blood samples
Description: Blood samples
Study: NCT00792493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741
Description: Alternating panel multiple dose escalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ORM-12741
Description: Alternating panel multiple dose escalation
Study: NCT00262938

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: behavioral dietary intervention
Description: Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling at baseline and at 3, 6, and 12 months. Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: counseling intervention
Description: Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling at baseline and at 3, 6, and 12 months. Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational intervention
Description: Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling at baseline and at 3, 6, and 12 months. Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: preventative dietary intervention
Description: Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling at baseline and at 3, 6, and 12 months. Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
Study: NCT01540955

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improving Cognition with group intervention
Description: Participants attend 5 weekly group sessions that are 2 hours each, delivered by a trained therapist. Sessions focus on specific aspects of attention, memory, multi-tasking and encoding. Homework assignments are practiced between classes. Goals are set for improved functioning.
Study: NCT03000439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: In open-label phase: treatment with tofacitinib
Description: Treatment with investigational drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: In double-blind phase: treatment with tofacitinib or placebo in 1:1 ratio
Description: Treatment with investigational drug or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: In double-blind phase: treatment with tofacitinib or placebo in 1:1 ratio
Description: Treatment with investigational drug or placebo
Study: NCT03213171

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reception staff providing handout.
Description: Reception staff will provide an educational pamphlet to patients that have not yet registered for organ donation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Tablet (e.g. iPad)
Description: Patients will have the opportunity to immediately register for organ donation using an a mobile tablet (e.g. IPad)
Study: NCT01421472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-121
Description: MM-121 IV at 40 mg/mg loading dose on Cycle 1, Week 1 followed by 20 mg/mg weekly for all subsequent doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Standard dosing of paclitaxel IV, followed by standard dosing of doxorubicin IV plus cyclophosphamide IV, followed by surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Standard dosing of paclitaxel IV, followed by standard dosing of doxorubicin IV plus cyclophosphamide IV, followed by surgery.
Study: NCT02491294

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School
Description: students receive Cooking With Kids (CWK) - Colorado cooking \& tasting lessons, SPARK active recess, and Cafeteria Connections

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family
Description: students receive the FFF family component - family nights, parent blog, and action packs that go home after each CWK-Colorado lesson

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family
Description: students receive the FFF family component - family nights, parent blog, and action packs that go home after each CWK-Colorado lesson

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: About Eating
Description: parents who completed the parent survey are invited to access the 6 lesson online About Eating program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: About Eating
Description: parents who completed the parent survey are invited to access the 6 lesson online About Eating program
Study: NCT01914562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCA 10 mg
Description: OCA 10 mg tablet oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCA 10 mg
Description: OCA 10 mg tablet oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCA 25 mg
Description: OCA 25 mg tablet oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCA 25 mg
Description: OCA 25 mg tablet oral
Study: NCT03516344

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver pumping and Spinal manipulation
Description: Interventions are described in group descriptions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver pumping and Spinal manipulation
Description: Interventions are described in group descriptions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver pumping and Spinal manipulation
Description: Interventions are described in group descriptions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver pumping and Spinal manipulation
Description: Interventions are described in group descriptions
Study: NCT00049088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT04078698

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immunoadsorber GLOBAFFIN®
Description: Documentation of the treatment with one of the immunoadsorber GLOBAFFIN® depending on the patient's underlying disease
Study: NCT01517477

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iStent
Description: Implantation of One iStent through a small temporal clear corneal incision.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iStent
Description: Implantation of Two iStents through a small temporal clear corneal incision

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iStent
Description: Implantation of Three iStents through a small temporal clear corneal incision
Study: NCT02467530

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AGE
Study: NCT01785212

Intervention type: DEVICE
Group type: OTHER
Intervention: Stapler
Description: stapler hepatectomy

Intervention type: DEVICE
Group type: OTHER
Intervention: CUSA (Cavitron ultrasonic aspirator; Valleylab, Boulder, CO)
Description: CUSA is a well established device used for hepatic resection using ultrasound
Study: NCT00929071

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evolence
Description: Injectable collagen

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evolence
Description: Injectable collagen

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: admix anesthetic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical anesthetic
Study: NCT01848535

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: GOS addition
Description: GOS (2.5g 3x per day) supplemented during 12 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: GOS addition
Description: GOS (2.5g 3x per day) supplemented during 12 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrine(2.5g 3x per day) supplemented during 12 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrine(2.5g 3x per day) supplemented during 12 days
Study: NCT04668352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dactolisib
Description: TORC1 inhibitor

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01976559

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tympanic Membrane Displacement (TMD)
Description: The CCFP Analyser has a passive mode and an active mode. When used in active mode, the device generates a tone burst that is transmitted to the ear to elicit contraction of the stapedius muscle. The passive mode requires no stimulus or sound burst.~For each ICP level during the CSF infusion testing, the active mode will be used. Each condition comprises 13 stimuli of 0.3s duration.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DPOAE
Description: DPOAE measurement uses a clinical acoustic probe to record the ear's response to two simultaneous tones. DPOAE measurements will be made for 13 tones. The total measurement time for each condition is 2-4 minutes.
Study: NCT03008395

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMMA
Description: Dialogue tools will be used to develop personally relevant behavioural goals consistent with diabetes self-management

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Participants randomized to this intervention will receive standard diabetes education sessions. These include group education session and follow up session based on clinician-generated recommendations.
Study: NCT02679469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nalmefene hydrochloride 10 mg
Study: NCT03739073

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OCTA (angiography by tomography in optical coherence)
Description: The study concerns patients with intermediate stenosis of the left anterior descending artery (LDA). A fundus oculi and an OCTA (angiography by tomography in optical coherence) examination will be performed; it's a non-invasive imaging test. OCT uses light waves to take cross-section pictures of your retina and then ophthalmological examination data will correlate with coronary angiography.
Study: NCT02809287

Intervention type: PROCEDURE
Intervention: Jackknife posture
Description: patients with left lateral position plus jackknife position when perform laparoscopic hepatectomy
Study: NCT01079481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taxol plus everolimus
Description: taxol 175mg/m2 every 3 weeks plus everolimus every day. The dose of everolimus will be started from 2.5mg per day, and increasing to 5mg per day and to 10mg per day.
Study: NCT00300638

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging (MRI)
Description: We present emotional words and pictures on a computer screen, and using MRI scans, we observe how the brain works when people purposefully respond to the words and pictures. Additionally, we are comparing brain structure and activation patterns in men and women, because there may be gender differences in responses to emotional stimuli.

Intervention type: BEHAVIORAL
Intervention: Interviews, cognitive tests, and emotional measurements
Description: We present emotional words and pictures on a computer screen, and using MRI scans, we observe how the brain works when people purposefully respond to the words and pictures. Additionally, we are comparing brain structure and activation patterns in men and women, because there may be gender differences in responses to emotional stimuli.
Study: NCT02935400

Intervention type: DRUG
Intervention: Hemin
Description: Hemin will be administered under a separate protocol or for clinical treatment, and samples will be collected under this protocol before and after treatment.
Study: NCT03473561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Racecadotril plus ORS
Description: 1.5 mg/kg of Racecadotril will be administered, 3 times daily, via the oral route (in addition to standard treatment i.e. oral rehydration solution).~In infants less than 9 kg: one 10 mg sachet 3 times daily. In infants from 9 kg to \< 13 kg: two 10 mg sachets 3 times daily. In children from 13 kg to 27 kg: one 30 mg sachet 3 times daily. In children of more than 27 kg: two 30 mg sachets 3 times daily.
Study: NCT03376672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: All patients will have similar induction and consolidation treatment with the same regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: All patients will have similar induction and consolidation treatment with the same regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: All patients will have similar induction and consolidation treatment with the same regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: All patients will have similar induction and consolidation treatment with the same regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: All patients will have similar induction and consolidation treatment with the same regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: All patients will have similar induction and consolidation treatment with the same regimen.
Study: NCT01175044

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Betadine Lavage
Description: Following revision knee surgery, a dilute betadine lavage prior to surgical closure for 3 minutes followed by 2000 ml of sterile saline irrigation

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Saline Lavage
Description: Following revision knee surgery, 2000ml sterile saline lavage prior to closure
Study: NCT01266486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Extended release Metformin 1500mg once daily for 14-21 days
Study: NCT02294513

Intervention type: DEVICE
Intervention: Standard audiologic rehabilitation (incl. HI)
Description: The intervention consists of standard audiologic rehabilitation in which participants are fit with at least one hearing instrument (HI).
Study: NCT01553838

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI guided prostate biopsy and TRUS guided biopsy
Description: MRI guided prostate biopsy
Study: NCT00565448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Pharmaceutical form:solution for infusion~Route of administration:intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: Pharmaceutical form:solution for infusion~Route of administration:intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Pharmaceutical form:solution for infusion~Route of administration:intravenous
Study: NCT00272987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: (GW572016) 1000 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: (GW572016) 1000 mg QD
Study: NCT01175083

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK1024850A (Synflorix)
Description: 2, 3 or 4 intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK1024850A (Synflorix)
Description: 2, 3 or 4 intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK1024850A (Synflorix)
Description: 2, 3 or 4 intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK1024850A (Synflorix)
Description: 2, 3 or 4 intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK1024850A (Synflorix)
Description: 2, 3 or 4 intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK1024850A (Synflorix)
Description: 2, 3 or 4 intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tritanrix-HepB/Hib
Description: Intramuscular injection, 4 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix-HepB/Hib
Description: Intramuscular injection, 4 doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Polio Sabin
Description: 4 oral doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polio Sabin
Description: 4 oral doses
Study: NCT02302612

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CREATE Wellness
Description: Patients allocated to the intervention arm will receive three group sessions with between visit contacts designed to increase activation and engagement with their care plans. They will also continue to be enrolled in the KP PHASE program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Control
Description: Patients allocated to the control arm will continue to receive usual care, including disease management within the KP PHASE program.
Study: NCT00753246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nimotuzumab
Description: monoclonal antibody

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nimotuzumab
Description: monoclonal antibody